The answer to big pharma's biggest problem could double your money in just three years

You are receiving this as part of your subscription to Strategic Tech Investor. To remove your email from this list, unsubscribe here.

A Brand-New Cannabis Investing Method Just Went Live (It Could Make You $17,500 in 24 Hours) For the first time ever, there is a brand-new way to play the cannabis market... and America's #1 Pattern Trader Tom Gentile is blowing the lid off. Thanks to the SEC allowing this, there is nothing stopping the average Joe from tapping into this extraordinary new profit stream... and potentially making tens of thousands of dollars every single week. Get all the details here. October 29, 2019 The Answer to Big Pharma's Biggest Problem Could Double Your Money in just Three Years (Click here to view this report online.) By Michael A. Robinson Dear Strategic Tech Investor Reader, LATEST APPEARANCE Why Wall Street Is Wrong About China and the Chip Sector, and Who is Leading the Rally MICHAEL'S LATEST ALERTS Research Why We're Selling Nokia Trading What Sold Out Rock Shows Say About the Market You could forgive drug and biotech executives for having a bad case of target fixation. After all, they do work in a field that is filled with time-consuming and expensive headaches. Consider that the Biotechnology Innovation Organization (BIO), the world's largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates. The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That's a one-in-ten shot. With such daunting data, it's no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market. And with that goal in mind, I've uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector's success. It's a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It's been doubling its earnings, on average, every 18 months... It's a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It's been doubling its earnings, on average, every 18 months... What I'm following... How to Double Your Money in Low-Risk Opportunities With credit conditions remaining excellent as the economy stays positive, the consensus of insiders is that the current state of banking is too good to pass up. One day Wall Street will wake up to the incredible earnings power of this sector, and until then you need to get in first on the best growth story in the market today. But that won't be a problem for Tim Melvin, who has developed a strategy replicating outstanding long-term gains without the same risks that cost most investors a fortune. Tim Melvin has found the financial superstars that could make massive gains all but imminent and secure. Click here to sign up for Tim Melvin's twice-weekly Max Wealth. This is your chance to access our biggest trading secrets (for only $1) This Seven-Day Cash Course covers all the essential trading ideas you NEED to know to get the most out of your potential profits in 2019. And not only will I cover the basics, I'll share dozens of my most lucrative secrets to potentially start collecting anywhere from $1,190, $1,313, and even $2,830 in consistent income - without buying a single share of stock up front. Here's the full story... CBD Could Grow 15X FASTER than the Overall Cannabis Market The CBD market is growing at warp speed. In fact, experts predict that sales in the hemp CBD sector will jump 3,622% in the next three years alone. And if you play your cards right, you could pocket gains up to 1,000%. We've identified two companies with massive profit potential in this industry... and they're both trading for under $4. Find out more here. Today: Anyone Can Become an Angel Investor with as Little as $50 Angel investing used to be off-limits to the average American... but Robert Herjavec said it best during this live broadcast: "The walls have finally come down. You no longer have to be rich, famous, or powerful to become an angel investor!" Congress has now made it possible for you to take advantage of these life-changing deals. By becoming an angel investor, you can be right there - one of the first to invest in the next Steve Jobs, the next Bill Gates, or the next Elon Musk. And because you're there at the beginning, the upside is infinitely greater. For so long, regular folks have been locked out... but not anymore. YOU MAY HAVE MISSED... Legendary angel investor wants to show you the deals he's personally willing to invest in (find out more) This is unlike anything you have ever seen before A new era of medicine is here (and you can profit from it) New feature has been recently embedded into major trading platforms You are receiving this e-mail at, its028@gmail.com, as a part of your free subscription to Strategic Tech Investor. Remove your email from this list: Unsubscribe Manage Your Email Preferences To cancel by mail or for any other subscription issues, write us at: Strategic Tech Investor | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201 North America: 888.384.8339; International: 443.353.4519; Fax: 410.622.3050 Contact Customer Service Website: https://strategictechinvestor.com/ © 2019 Strategic Tech Investor All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Strategic Tech Investor. 1125 N Charles Street, Baltimore MD 21201.